Antibody-CdtB Conjugates for Selective Lymphocyte Arrest
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies fail to effectively inhibit and utilize cytolethal distending toxins (Cdt) for therapeutic purposes, particularly in addressing lymphoproliferative, hypersensitivity, inflammatory, and autoimmune diseases, due to the unclear mechanisms of CdtB's action and its high sensitivity in lymphocytes.
Innovation Solution
Administration of CdtB toxin, Cdt holotoxin, or mutant forms to arrest lymphocyte cells at the G2 phase, leveraging their PI-3,4,5-P3 phosphatase activity to treat lymphoproliferative, hypersensitivity, inflammatory, and autoimmune diseases, and inhibiting CdtB activity for infectious diseases caused by bacterial pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CdtB toxin is used to treat lymphoproliferative diseases by arresting lymphocyte cells at G2 phase, then therapeutic effect is improved, but high sensitivity of lymphocytes to Cdt (5 orders of magnitude more sensitive than other cells) creates difficulty in controlling dosage and avoiding off-target effects
Solution Approach 1:
The patent uses an antibody-CdtB conjugate as an intermediary system. The antibody component specifically targets lymphocyte surface markers, delivering the CdtB toxin selectively to lymphocytes while sparing other cell types. This mediator approach resolves the contradiction by enabling controlled delivery to the highly sensitive target cells without affecting other tissues.
Solution Approach 2:
The invention applies local quality by making the toxin delivery selective to specific lymphocyte populations through antibody targeting. Different antibody specificities can be used to target different lymphocyte subsets (B cells, T cells, etc.), allowing precise control over which lymphocyte populations are affected while leaving other cells untouched.
2Reliability
If CdtB toxin is administered to arrest lymphocyte cell cycle, then lymphoproliferative diseases are treated, but unclear mechanisms of CdtB action hinder effective inhibition strategies
Solution Approach 1:
The patent employs preliminary action by using antibodies to pre-target and bind to lymphocyte surface markers before CdtB toxin delivery. This preliminary binding step ensures specific localization of the toxin to the intended target cells, overcoming the mechanism uncertainty by creating a controlled delivery system that bypasses the need to fully understand all aspects of CdtB's natural mechanism.
Solution Approach 2:
The invention incorporates feedback mechanisms through the use of antibody-based targeting systems that can be monitored and adjusted. By using well-characterized antibody-antigen interactions as a feedback loop, the system provides controllable and measurable delivery of CdtB toxin, allowing optimization of dosage and timing despite uncertainties about CdtB's complete mechanism of action.
3Adaptability or versatility
If Cdt holotoxin is used for treating hypersensitivity and inflammatory diseases, then immune response is modulated, but potential harmful effects on other cell types must be avoided
Solution Approach 1:
The patent uses antibody-CdtB conjugates as intermediaries to deliver the toxin selectively to lymphocytes involved in hypersensitivity and inflammatory responses. The antibody component acts as a mediator that spares other cell types, allowing the CdtB toxin to modulate immune responses without causing harmful effects on non-lymphocyte tissues.
Solution Approach 2:
The invention applies local quality by directing the toxin's effect specifically to lymphocyte populations involved in pathological immune responses. Through antibody targeting, the system achieves local modulation of immune function in affected tissues while leaving other organ systems unaffected, enabling treatment of hypersensitivity and inflammatory diseases with minimal off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively treats and suppresses lymphoproliferative, hypersensitivity, inflammatory, and autoimmune diseases by arresting lymphocyte cell cycle and reducing PI-3,4,5-P3 levels, while also providing a method to inhibit Cdt toxin activity in infectious diseases.
Implementation Method 1
leveraging their PI-3,4,5-P3 phosphatase activity to treat lymphoproliferative, hypersensitivity, inflammatory, and autoimmune diseases
Data Source
AI summary
This invention relates to immunotoxins and their use. Specifically, the invention relates to compositions comprising Cdt toxins or their inhibitors and their use in methods for treating infectious and proliferative diseases.